Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy

2002 ◽  
Vol 9 (10) ◽  
pp. 961-967 ◽  
Author(s):  
S. van Ruth ◽  
A. A. M. Hart ◽  
J. M. G. Bonfrer ◽  
V. J. Verwaal ◽  
F. A. N. Zoetmulder
Keyword(s):  
Carcinoembryonic Antigen ◽  
Intraperitoneal Chemotherapy ◽  
Pseudomyxoma Peritonei ◽  
Prognostic Value ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Carbohydrate Antigen

Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels

2020 ◽  
pp. 1-6
Author(s):  
Daxin Huang ◽  
Qingliang Lin ◽  
Jianyuan Song ◽  
Benhua Xu
Keyword(s):  
Rectal Cancer ◽  
Carcinoembryonic Antigen ◽  
Prognostic Value ◽  
Locally Advanced ◽  
Prognostic Significance ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Carbohydrate Antigen ◽  
Curative Surgery ◽  
Pretreatment Serum

<b><i>Background:</i></b> Elevated pretreatment carcinoembryonic antigen (CEA) levels are related to poor prognosis in patients with locally advanced rectal cancer (LARC) treated with neo-CRT followed by TME. In patients with normal pretreatment CEA levels, the prognostic significance of carbohydrate antigen 199 (CA199) is controversial. <b><i>Objectives:</i></b> The aim of this study was to explore the prognostic value of pretreatment serum CA199 in patients with LARC who had normal pretreatment CEA levels treated with neo-CRT followed by curative surgery. <b><i>Methods:</i></b> A retrospective study of 456 patients with LARC treated with neo-CRT followed by TME between January 2006 and May 2017 was performed. We employed the maximal χ<sup>2</sup> method to determine the CA199 threshold of 9.1 U/mL based on the difference in survival and divided patients into 2 groups. Group 1: patients with pretreatment s-CEA &#x3c; 5 ng/mL and CA199 ≥ 9.1 U/mL. Group 2: patients with pretreatment s-CEA &#x3c; 5 ng/mL and CA199 &#x3c; 9.1 U/mL. Overall survival (OS) across CA199 was assessed using Cox proportional hazard regression models (PS:CEA ≥ 5 ng/mL was seen as elevated). <b><i>Results:</i></b> Multivariate analyses demonstrated that the following factors were significantly related to OS in patients with LARC with normal pretreatment CEA levels: ypT (odds ratio [OR] 1.863, <i>p</i> = 0.030), ypN (OR 1.622, <i>p</i> = 0.026), and pretreatment CA199 levels (OR 1.886, <i>p</i> = 0.048). <b><i>Conclusion:</i></b> Pretreatment CA199 is an independent factor for OS in patients with LARC with normal pretreatment CEA levels, which may reach the clinic to guide individualized decision-making.

Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre

2011 ◽  
Vol 13 (4) ◽  
pp. 261-267 ◽  
Author(s):  
Álvaro Arjona-Sánchez ◽  
Francisco C. Muñoz-Casares ◽  
Sebastián Rufián-Peña ◽  
Rafael Díaz-Nieto ◽  
Ángela Casado-Adam ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Pseudomyxoma Peritonei ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Single Centre
Sign in / Sign up

Export Citation Format

Share Document